Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

Abstract

Many patients receiving pasireotide do not develop hyperglycemia requiring oral antidiabetic drugs. Metformin is an effective initial treatment, followed by incretin-based therapy if needed. ClinicalTrials.gov ID: NCT02060383.